Data from Ladoire et al. (2008) showed that a systemic anthracycline-based NACT in early-stage breast cancer patients resulted in a decreased infiltration of Treg cells whereas the level of CD8+ T cell infiltration remained unchanged in complete responders [23]. This evidence concerns the gene CD8A and breast cancer.